Today, Cambrex announced its stability storage business, Q1 Scientific, and opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to North America's pharmaceutical, medical device, and life sciences industries.
Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical ingredient (API) batch reactors and continuous flow.
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Noramco, a US producer of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. Financial details were not disclosed.
US CDMO Cambrex has agreed to buy Snapdragon Chemistry, a compatriot company specializing in developing continuous flow and batch processes for APIs. Snapdragon is based in Waltham, Massachusetts, where it employs 74 people.
Cambrex is investing in a new R&D facility in Minneapolis, Minnesota, USA, expanding its capacity for small molecule development and manufacturing.
US CDMO Cambrex has upgraded its facility in Tallin, Estonia. The installation of a new 160-liter reactor train at the kilogram-scale laboratory has expanded Cambrex’s capabilities to manufacture material for clinical trials and allow early-phase projects to be developed further prior to technical transfer and scale-up.
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
Cambrex is spending $3.6 million to expand flexible drug substance manufacturing at its site in Karlskoga, Sweden. Engineering has already begun, and work is expected to be completed by November 2020.
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
